OCT 2026

LIVE WEBINAR · BREAST CANCER (HR+/HER2− METASTATIC) · THURSDAY 15 OCTOBER · 4:00 PM CET / 10:00 AM ET · 45 MINUTES

Inside GOLF: how 77+ of the world's top breast cancer doctors are tracked all year — and what they're saying going into ESMO 2026

15 October 2026, 14:00 UTC · 45 min

This is not a congress-coverage webinar. It is a 45-minute look inside GOLF — the only always-on KOL intelligence system in HR+/HER2− metastatic breast cancer. ESMO Madrid is simply the next event it will measure.

Speakers

Tanvi Bahl · Bhawna Jethani

Save my seat

We'll send the joining link right away, and the replay afterward.

Can't make it live? Register anyway — every registrant receives the replay.

Your presenters

Tanvi Bahl

Director, Global Oncology Leadership Forum, GRG Health

Tanvi leads the GOLF programme end to end — the KOL sessions, the field surveys, and the intelligence delivered to pharma teams.

Bhawna Jethani

Head, Quality Assurance, GRG Health

Bhawna is head of insights quality on GOLF, responsible for the checks every readout passes before it reaches a pharma team.

What you will see

How the machine works. Since January 2026, leading breast cancer doctors across 10 countries have been meeting on GOLF — independently moderated, no drug company in the room, everything recorded. You'll see how their discussions become drug-by-drug intelligence: 1,400+ opinion scores across 45 drugs, 290+ tagged insights for Medical, Commercial and Market Access teams, and 760+ field-survey answers testing whether practicing oncologists actually follow the experts.
What it caught in 2026. The oral SERD class has moved four times since July — new approvals, new combinations, new owners. We'll show you, with real (anonymised) examples, what the doctors said before the press releases, and where expert opinion and real-world practice still disagree.
What the doctors are saying going into Madrid. The late-breaking titles are out. We'll walk through what GOLF's KOLs expect from ESMO 2026 — and what would have to happen in Madrid to change how they treat.
How your team plugs in. How pharma teams use GOLF all year — and how the six-seat ESMO 2026 programme works as the entry point, with every dollar crediting toward membership.

Who should attend

Medical Affairs, Competitive Intelligence, Commercial/Brand, and Market Access professionals working on any asset in the HR+/HER2− metastatic breast cancer landscape — oral SERDs, CDK4/6 inhibitors, PI3K/AKT-pathway agents, ADCs, and endocrine therapy.

An independent research programme by GRG Health — not affiliated with, sponsored or endorsed by ESMO. For research purposes only · Not for promotional use · Conducted under EFPIA & PhRMA principles · KOL statements recorded with consent · © GRG Health 2026 · Questions: tanvi.bahl@grgonline.com